ALS ONE's 5th Annual ALS ONE Research Symposium, held Oct. 6, 7, & 11, 2022, hosted by our research team: Dr’s Merit Cudkowicz, MD, MSc of MGH, Robert H Brown, Jr. MD, DPhil of UMass Medical School, James Berry, MD, MPH of MGH, Sabrina Paganoni, MD, PhD of MGH, and Fernando Vieira, MD of ALS TDI, and in collaboration with Indu Navar, Dr. Shel Lalji and Dr. Leigh Hochberg for Day 3's Neurotechnology Day. The conference had over 960 registered guests from 34 countries, including researchers, scientists, and members of the ALS community from around the world, convening virtually for 3 days of sharing critical research that is underway across the globe to help uncover therapeutic options leading to an ultimate cure for Amyotrophic Lateral Sclerosis (ALS). Recordings were made of the presentations which we are/were approved to share.
IN THIS VIDEO:
Symposium Segment: Industry Presentations
Presentation Title: The Relationship Between CSFBiomarkers and Efficacy of Treatment with NurOwn (MSC-NTF).
Speaker: Stacy Lindborg, PhD, Executive Vice President and Chief Development Officer at Brainstorm-Cell Therapeutics.
Moderated by: Robert H. Brown, Jr. MD, DPhil, Chief of Neurology at UMass Chan Memorial Medical School.
To learn more about this year's Symposium, visit: [ Ссылка ]
ALS ONE is a 501c3 non-profit organization focused entirely on ALS research and care. To learn more about ALS ONE or to support our mission, visit: www.alsone.org.
